Literature DB >> 23566996

Feasibility of adjacent insulin infusion and continuous glucose monitoring via the Medtronic Combo-Set.

David N O'Neal1, Sumona Adhya, Alicia Jenkins, Glenn Ward, John B Welsh, Gayane Voskanyan.   

Abstract

BACKGROUND: Subcutaneously infused insulin may interfere with the function of nearby glucose-sensing electrodes and vice versa. The prototype of the Combo-Set device (Medtronic) incorporates a subcutaneous insulin delivery catheter and continuous glucose monitoring (CGM) sensor assembled on the same platform and separated by 11 mm. We aim to evaluate Combo-Set's insulin delivery and glucose-sensing functions.
METHODS: Ten subjects with type 1 diabetes wore a Combo-Set and a Sof-Sensor inserted subcutaneously in contralateral abdominal areas connected to iPro recorders (Medtronic) for 53.25 ± 0.75 h (mean ± standard deviation). The Combo-Set delivered insulin diluent except during meal tests on days 1 and 3 when insulin lispro was delivered as a meal bolus and postmeal basal. Venous plasma samples were collected at the following time points from meal start: 0, 30, 60, 120, and 180 min for insulin measurements. The accuracy of the Combo-Set sensors was evaluated and compared with that of the Sof-Sensor, with each referenced against capillary glucose values (Contour Link Meter, Bayer).
RESULTS: Accuracy of the Combo-Set sensor was comparable to that of the Sof-Sensor. Clarke error grid analysis showed that 97% of Combo-Set and 93% of Sof-Sensor values were in the A+B regions (p = .20, not significant). The Combo-Set showed the expected postbolus peak insulin time (67 ± 9 min, mean ± standard error). One "no delivery" alarm occurred during the 21 patient days of use.
CONCLUSION: A device providing for simultaneous adjacent placement of an insulin infusion catheter and a CGM sensor is feasible and functions within acceptable limits. The low "no delivery" alarm rate was similar to that of other infusion sets.
© 2013 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23566996      PMCID: PMC3737639          DOI: 10.1177/193229681300700214

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  18 in total

1.  The MiniMed continuous glucose monitoring system.

Authors:  J J Mastrototaro
Journal:  Diabetes Technol Ther       Date:  2000       Impact factor: 6.118

2.  Evaluating in vitro and in vivo the interference of ascorbate and acetaminophen on glucose detection by a needle-type glucose sensor.

Authors:  D Moatti-Sirat; G Velho; G Reach
Journal:  Biosens Bioelectron       Date:  1992       Impact factor: 10.618

3.  Clinical experience with an integrated continuous glucose sensor/insulin pump platform: a feasibility study.

Authors:  John J Mastrototaro; Ken W Cooper; Gopi Soundararajan; Jeff B Sanders; Rajiv V Shah
Journal:  Adv Ther       Date:  2006 Sep-Oct       Impact factor: 3.845

4.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Authors:  R C Turner; C A Cull; V Frighi; R R Holman
Journal:  JAMA       Date:  1999-06-02       Impact factor: 56.272

5.  Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial.

Authors:  Richard R Rubin; Mark Peyrot
Journal:  Diabetes Technol Ther       Date:  2011-12-01       Impact factor: 6.118

6.  Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy.

Authors:  Stuart Weinzimer; Dongyuan Xing; Michael Tansey; Rosanna Fiallo-Scharer; Nelly Mauras; Tim Wysocki; Roy Beck; William Tamborlane; Katrina Ruedy
Journal:  Pediatr Diabetes       Date:  2008-10-20       Impact factor: 4.866

7.  No apparent local effect of insulin on microdialysis continuous glucose- monitoring measurements.

Authors:  Jeroen Hermanides; Iris M Wentholt; Augustinus A Hart; Joost B Hoekstra; J Hans DeVries
Journal:  Diabetes Care       Date:  2008-03-10       Impact factor: 19.112

8.  Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study.

Authors:  Irl B Hirsch; Jill Abelseth; Bruce W Bode; Jerome S Fischer; Francine R Kaufman; John Mastrototaro; Christopher G Parkin; Howard A Wolpert; Bruce A Buckingham
Journal:  Diabetes Technol Ther       Date:  2008-10       Impact factor: 6.118

9.  Continuous glucose monitoring and intensive treatment of type 1 diabetes.

Authors:  William V Tamborlane; Roy W Beck; Bruce W Bode; Bruce Buckingham; H Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Irl B Hirsch; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Lori Laffel; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing
Journal:  N Engl J Med       Date:  2008-09-08       Impact factor: 91.245

10.  Continuous glucose sensing: future technology developments.

Authors:  Jim Brauker
Journal:  Diabetes Technol Ther       Date:  2009-06       Impact factor: 6.118

View more
  8 in total

Review 1.  Moving Toward a Unified Platform for Insulin Delivery and Sensing of Inputs Relevant to an Artificial Pancreas.

Authors:  Anneke Graf; Sybil A McAuley; Catriona Sims; Johanna Ulloa; Alicia J Jenkins; Gayane Voskanyan; David N O'Neal
Journal:  J Diabetes Sci Technol       Date:  2016-12-13

2.  Benefits and Limitations of MARD as a Performance Parameter for Continuous Glucose Monitoring in the Interstitial Space.

Authors:  Lutz Heinemann; Michael Schoemaker; Günther Schmelzeisen-Redecker; Rolf Hinzmann; Adham Kassab; Guido Freckmann; Florian Reiterer; Luigi Del Re
Journal:  J Diabetes Sci Technol       Date:  2019-06-19

3.  Continuous glucose monitoring in 2013.

Authors:  Tadej Battelino; Bruce W Bode
Journal:  Diabetes Technol Ther       Date:  2014-02       Impact factor: 6.118

Review 4.  Can glucose be monitored accurately at the site of subcutaneous insulin delivery?

Authors:  W Kenneth Ward; Jessica R Castle; Peter G Jacobs; Robert S Cargill
Journal:  J Diabetes Sci Technol       Date:  2014-02-18

5.  Performance and acceptability of a combined device for insulin infusion and glucose sensing in the home setting.

Authors:  Kirsten Nørgaard; John Shin; John B Welsh; Hans Gjessing
Journal:  J Diabetes Sci Technol       Date:  2015-01-14

Review 6.  Influences on Technology Use and Efficacy in Type 1 Diabetes.

Authors:  Victoria Franklin
Journal:  J Diabetes Sci Technol       Date:  2016-05-03

7.  Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes.

Authors:  Andrew W Karlin; Trang T Ly; Laura Pyle; Gregory P Forlenza; Laurel Messer; R Paul Wadwa; Daniel J DeSalvo; Sydney L Payne; Sarah Hanes; Paula Clinton; David M Maahs; Bruce Buckingham
Journal:  Diabetes Technol Ther       Date:  2016-05-26       Impact factor: 6.118

8.  Measuring glucose at the site of insulin delivery with a redox-mediated sensor.

Authors:  Peter G Jacobs; Nichole S Tyler; Scott M Vanderwerf; Clara Mosquera-Lopez; Thomas Seidl; Robert Cargill; Deborah Branigan; Katrina Ramsey; Kristin Morris; Sheila Benware; W Kenneth Ward; Jessica R Castle
Journal:  Biosens Bioelectron       Date:  2020-04-29       Impact factor: 12.545

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.